Your browser doesn't support javascript.
loading
A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.
Stathopoulos, Georgios T; Psallidas, Ioannis; Moustaki, Ardiana; Moschos, Charalampos; Kollintza, Androniki; Karabela, Sophia; Porfyridis, Ilias; Vassiliou, Spyridoula; Karatza, Marilena; Zhou, Zongmin; Joo, Myungsoo; Blackwell, Timothy S; Roussos, Charis; Graf, Daniel; Kalomenidis, Ioannis.
Afiliação
  • Stathopoulos GT; Applied Biomedical Research and Training Center Marianthi Simou, Department of Critical Care and Pulmonary Services, General Hospital Evangelismos, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. gstathop@med.uoa.gr
J Natl Cancer Inst ; 100(20): 1464-76, 2008 Oct 15.
Article em En | MEDLINE | ID: mdl-18840818
BACKGROUND: Tumor cells in malignant pleural effusions (MPEs) are an important source of monocyte chemoattractant protein (MCP)-1. However, the role of tumor-derived MCP-1 in the pathogenesis and progression of MPE has not been determined. METHODS: B16 mouse skin melanoma cells, which are deficient in MCP-1 expression, and mouse Lewis lung cancer (LLC) cells, which express high levels of MCP-1, were engineered to stably express MCP-1 and short hairpin RNAs (shRNAs) targeting the MCP-1 transcript, respectively. Cells were injected into the pleural cavities of syngeneic immunocompetent mice, and MPE volume and pleural tumors were quantified at necropsy (day 14). MCP-1 and other mediators were determined by cytometric bead array and enzyme-linked immunosorbent assay, and mononuclear and endothelial cells were identified by immunolabeling of F4/80 and factor VIII-related antigen respectively. Mouse survival was assessed using Kaplan-Meier analysis. Vascular permeability in mice with MPE was assessed using albumin-binding Evans blue. Statistical tests were two-sided. RESULTS: LLC cells expressing shRNA against MCP-1 elaborated less than 5% of the MCP-1 level in cells expressing nonspecific shRNA (control cells), and intrapleural delivery of these cells resulted in less MPE (mean MPE volume = 86 and 585 muL, respectively; difference = 499 muL; 95% confidence interval [CI] = 331 to 669 muL; P < .001), reduced MCP-1 levels in the pleural fluid, and lower mortality than when control cells were delivered. Overexpression of MCP-1 in intrapleurally injected B16 melanoma cells led to increased MPE and reduced survival. In mice with MPE, MCP-1 was a potent inducer of vascular permeability, mononuclear recruitment, and, in pleural tumors, of angiogenesis. CONCLUSION: MCP-1 produced by tumor cells is an important determinant of their capacity to induce the formation of MPE and may be a useful target for the treatment of malignant pleural disease.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Derrame Pleural Maligno / Quimiocina CCL2 / Neoplasias Experimentais Tipo de estudo: Prognostic_studies Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2008 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Derrame Pleural Maligno / Quimiocina CCL2 / Neoplasias Experimentais Tipo de estudo: Prognostic_studies Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2008 Tipo de documento: Article